Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech giants dominate?
By 2026, the number of people using digital therapeutics is estimated to increase by 381%, reaching a market size of $28 billion. This makes digital therapeutics the fastest-growing field in digital health.
Digital therapeutics are evidence-based therapeutic interventions, designed to prevent, manage, or treat a variety of medical conditions, ranging from chronic diseases and neurological disorders to tackling challenges such as medication adherence.
The benefits are far-reaching, from optimizing patient outcomes to reducing the economic burden on healthcare systems. However, the real value lies when digital therapeutics are combined with a medicinal asset. This powerful combination uncovers a wealth of untapped opportunities for biopharmaceutical companies to maximize the value of medicinal assets, driving differentiation and increasing access to safe and effective therapies.
To capitalize on this opportunity, the digital therapeutic must support an asset to fulfill an unmet need. However, as tech giants shape this arena and more needs are catered to, it will become difficult to develop digital platforms that increase value for all stakeholders. As a result, early market entry is fundamental.
In this whitepaper, our consultants explore the market landscape and provide strategic recommendations for manufacturers to leverage the power of digital therapeutics to enhance the value of products and portfolios including:
- Digital therapeutics market growth
- Key therapy areas and applications
- Detailed benefits for stakeholders and advice on overcoming adoption hurdles
- Strategic recommendations for developing a digital therapeutics commercialization strategy that crystalizes the value of an asset
In October 2023, Fishawack Health rebranded to Avalere Health, unifying our organization under a single team and vision to faster connect patients with life-enhancing therapies.